secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2023-08-30T23:59:59+00:00
Accession:  0000950170-23-045176
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes settles VIVITROL patent litigation with Teva; generic entry January 2027
--------------------------------------------------------------------------------

- Teva granted license to market generic VIVITROL in U.S. starting Jan 15, 2027, or earlier under certain circumstances.
- Settlement resolves lawsuit filed Sep 2020; trial completed Mar 2023; patent expires 2029.
- Agreement subject to FTC and DOJ review; parties will file joint stipulation to dismiss litigation.
- Financial terms not disclosed; license is non-exclusive, royalty-free, limited to Teva's ANDA product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/0000950170-23-045176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/alks-20230829.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-045176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer